Premature ejaculation (PE) is a common disease in the andrology clinic. Currently, the effectiveness and outcome differences of drug treatment still need to be studied and demonstrated. Premature ejaculation concurrent with erectile dysfunction (ED) is common in outpatient clinics. The preferred treatment plan for these patients still needs to be further studied and explored, and the difference in the efficacy of different treatment regiments remain to be evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
5 mg tablets every day for 8 weeks
5 mg tablets every day for 8 weeks
The change of Premature Ejaculation Profile (PEP) at week 8
The PEP is a 4-question PRO that asks a respondent about his subjective sense of control over ejaculation, distress related to PE, interpersonal difficulty and satisfaction with sexual intercourse.
Time frame: Baseline, Week 8
The change of International Index of Erectile Function -5(IIEF-5) at week 8
Time frame: Baseline, Week 8
Incidence of adverse reactions
To observe the safety of the two regiments in PE concurrent with ED patients
Time frame: Baseline, Week 8
The change of Erection Hardness Score (EHS)
Erection Hardness Score as a self-reporting measure that scored erection hardness on a 4 point scale. The aim was to help men, their partners and doctors diagnose erectile dysfunction.
Time frame: Baseline, Week 8
Clinical Global Impression of Change (GICC)
Clinical Global Impression is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.
Time frame: Baseline, Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.